Related Experiment Video
Updated: Jul 22, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
The antiatherogenic potential of blocking the renin-angiotensin system
1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St., Boston, MA 02115, USA.
Abstract:
Angiotensin converting enzyme (ACE) inhibitors have proved effective in preventing or ameliorating clinical manifestations of atherosclerosis, such as myocardial infarction (MI) and heart failure. Experimental evidence demonstrates their anti-atherogenic potential; ACE inhibitors do not only suppress the formation of proatherogenic angiotensin II (AII), but also enhance the formation and release of anti-atherogenic nitric oxide (NO) at local tissue sites; both mechanisms are implicated in the suppression of neointima formation in the balloon-injured vessel wall. A similar anti-atherogenic potential is provided by the blockade of the renin-angiotensin system (RAS) at the level of the angiotensin type-1 (AT1) receptor. AT1 receptor antagonists do not only block the proatherogenic actions of AII, but also induce an enhanced formation and release of anti-atherogenic NO at local tissue sites. AT1 receptor antagonists may therefore prove as effective as ACE inhibitors in patients with manifest atherosclerosis.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

